Natural killer cells: Cultivation, activation, and growth

BERGISCH GLADBACH, August 4, 2017 – Miltenyi Biotec extends its product portfolio in the area of cell culture media with the NK MACS® Medium
BERGISCH GLADBACH, August 3, 2017 – A new addition to the well-known product family of cell culture media: With the new NK MACS® Medium, human, Miltenyi Biotec offers a product to improve the cultivation of human natural killer cells, or NK cells as they are called. The biotechnology company from Bergisch Gladbach, already known as a longstanding partner in the field of translational NK cell research, can now offer access to fully functional expanded NK cells, which can be used in different downstream applications such as killing assays. 

As starting material, isolated human NK cells or PBMCs (peripheral blood mononuclear cells) can be used. When inititating the culture from PBMCs directly, the NK MACS Medium is advantageous over other media since the growth of undesired T and NKT cells (natural killer T cells) is minimal.

The medium in detail
Thanks to its defined composition the NK MACS Medium allows reproducible cell culture results. It contains stable glutamine and phenol red, and is produced free from animal-derived components and serum albumin – human serum or autologous plasma must be added to cultivate your cells. 

A successful cell culture portfolio
Along with the NK MACS Medium, Miltenyi Biotec offers several high-quality media in its product portfolio ‘MACS Cell Culture and Stimulation’, which contribute to a successful cell culture in stem cell research, the neurosciences, and immunology. In addition, a large number of cytokines, growth factors, and TLR (toll-like receptor) ligands are available that promote cell growth or cell differentiation into diverse lineages and support culture experiments in basic research or in the translational field.  

For further information see

Meet us at one of the following events:
September 4–5, 2017 DC Immunotherapy Day, Bergisch Gladbach, Germany
September 11–13, 2017 5. Annual Conference of the German Stem Cell Network, Jena, Germany
September 21–23, 2017 EMDS 2017 – European Macrophage & Dendritic Cell Society, Madrid, Spain

About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotec’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Their more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In their commitment to the scientific community, Miltenyi Biotec also offers comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 2,000 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health. For more information please visit

Press contact:
Miltenyi Biotec
Dr. Anna Guastafierro
Communications Manager 

Publication free of charge – Specimen copy requested.

Seems like you are coming from USA!
Do you want to visit our website in your country?